February 26, 2016 – Two new treatments for oncologic indications have been approved by the American Food and Drug Administration (FDA). Thus, the FDA approved Obinutuzumab (Gazyva) for use in combination with bendamustine followed by Obinutuzumab (Gazyva) monotherapy for the treatment of patients with follicular …

News for Obinutuzumab (Gazyva) and Everolimus (Afinitor) Read more »